Our team is engaged in clinical research in genetics and metabolism.

  • Dr. Adams is the Principal Investigator for the Treatment of Episodic Hyperammonemic Coma in Patients with Urea Cycle Disorder with Intravenous Sodium Phenylacetate/Sodium Benzoate.
  • Dr. Adams is also a Principal Investigator for Iduronate-2-Sulfatase Replacement Therapy in Mucopolysaccharidosis II (MPS II) which is an enzyme replacement therapy protocol currently in Phase III clinical trials for FDA approval. The Section is also pursuing funding from the NIH to evaluate precursors of Metabolic Obesity Syndrome (Syndrome X).